

An anatomical diagram of a human figure from the back, showing the circulatory and nervous systems. The heart is visible in the center, with red lines representing oxygenated blood flow and blue lines representing deoxygenated blood flow. A complex network of yellow and green lines represents the nervous system, branching out from the brain and spinal cord to the limbs and torso. The figure is centered on a dark, textured background.

Lab Seminar

Part B
Sept. 3, 2003

Computer-related issues

Why Linux?

Tiedät kyllä miksi



Actually only the heart of the operating system (the "kernel") is Finnish...

Computer-related issues

- Linux can run on different hardware: i386, PPC
- Different distributions (what programs are packaged, user interface):
 - RedHat or Suse for i386
 - Yellow Dog for PPC
- i386 Linux distributions are more advanced than PPC distributions
- When should you **NOT** switch to Linux?
 1. If you have trouble as a Mac user using Windows or as a Windows user using Macs
 2. If you have no time
 3. If you are generally not technically inclined

Computer-related issues



- Linux works, RedHat 9 on Celeron 500 MHz
- Connectivity: from Windows to Mac (both OS 9 and X) to Linux
from Linux to Mac OS X and Windows
- Many applications are available as Linux versions
Mozilla/Firebird/Netscape, Acrobat Reader, Citrix ICA Client
- There are Open Source alternatives for almost all applications
Photoshop: GIMP
MS Office: Open Office
QuickTime: Video LAN Client
Lasergene/Gene Construction Kit: Staden, Emboss
- Many Windows programs run on Linux **without emulation** using WINE
MS Office, Photoshop, Endnote, Internet Explorer
- All Windows programs run on Linux with emulation using VMware
- PPC Distributions: no WINE, instead MOL (Mac On Linux)

This presentation

- Alternative to PowerPoint:
XML or PDF? HTML/CCS2, advantages: file size, portability, output device independent
- Mac version of Opera browser doesn't support output device detection, for Mozilla in development
- Convert OpenOffice into PowerPoint presentation?
Works only if you haven't imported your graphics from other vector-based drawing programs (Freehand, CorelDraw, Adobe Illustrator)
- Install OpenOffice on Mac?
There is no native Mac OS X port of OpenOffice (coming in end of the year)
- Install X Windows, install the UNIX version of OpenOffice, convert Unix fonts into Macintosh fonts

VEGF-C

- What is known about the different forms of VEGF-C
- What to use when: Immunization, Lymphangiogenesis/Angiogenesis
- What attempts have been done to produce monoclonal antibodies against human VEGF-C?
- What antibodies do exist and what do they recognize?
- What are the differences between VEGF-C and VEGF-D?



Peptides (produced in 293 EBNA cells) identified by sequencing:

- NH₂-F(32)ESGLD
- NH₂-A(112)HYNTE
- NH₂-S(228)LPATL

α -VEGF-C/
 α -H₅

mVEGFR-2

hVEGFR-2

hVEGFR-3





Δ N Δ C
wild type
“cleavage-inhibited”
“uncleavable”

Δ N Δ C
wild type
“cleavage-inhibited”
“uncleavable”

Δ N Δ C
wild type
“cleavage-inhibited”
“uncleavable”


Δ N Δ C
wild type
“cleavage-inhibited”
“uncleavable”

46 —
30 —
21 —



kDa	form	VEGFR-2	VEGFR-3
58	full length	+/-	+
43	alternatively C-terminally processed	++	++
29/31	main/secreted	+	+++
21	mature	++	+++
15	N-terminal propeptide + partial VHD	-	-


Mature VEGF-C is probably a rare species under physiological conditions



	1		50		100	
human	MHLIGFFSVA	CSLLAAALLP	GPREAPAAAA	AFESGLDLSD	AEPDAGEATA	YASKDLEEQL
mouse	MHLLCFLSLA	CSLLAAALIP	SPREAPATVA	AFESGLGPSE	AEPDGGEVKA	FEGKDLEEQL
	103		150		200	227
human	TEETIKFAAA	HYNTEILKSI	DNEWRTQCM	PREV	CIDVGK	EFGVATNTFF
mouse	TGDSVKFAAA	HYNTEILKSI	DNEWRTQCM	PREV	CIDVGK	EFGAATNTFF
	228		250		300	330
human	SLPATLPQCQ	AANKTCPTNY	MWNNHICRCL	AQEDFMFSSD	AGDDSTDGFH	DICGPNKELD
mouse	SLPATLPQCQ	AANKTCPTNY	VWNNYMCRL	AQQDFIFYSN	VEDDSTNGFH	DVCGPNKELD
	331		350		400	419
human	NREFDENTCQ	CVCKRTCPRN	QPLNPGKCAC	ECTESPOKCL	LKGKKFHHQT	CSCYRRPCTN
mouse	NREFDENTCQ	CVCKRTCPRN	QPLNPGKCAC	ECTENTQKCF	LKGKKFHHQT	CSCYRRPCAN

102/103 111/112 219/220 227/228

..NLNSRTEETI KFAAAHYN... ..MSKLDVYRQVHSI IRRSLPAT...




VEGF-C antibodies


- 882: not for Western of 293 cells, maybe 1 ml left
- 905: N-terminal propeptide, IP works under non-reducing conditions
- new polyclonal sera 3 & 4: works in Western and IP, low titre
- new polyclonal sera 5 & 6: work well in Western and IP, not for Western of short form

All recombinant VEGF-C protein that has been shown to be lymphangiogenic in vivo was one of the following three forms:


▶ $\text{NH}_2\text{-(DP)TEETIK...MSKLH}_6\text{-COOH}$



▶ $\text{NH}_2\text{-(DP)AHYNT...MSKLD-myc-H}_6\text{-COOH}$



▶ $\text{NH}_2\text{-(DP)FESGL...RPQMS-H}_6\text{-COOH}$



Transgenic mice/Adenoviruses/AAV

- ▶ Adenovirus: NH_2 -TEETIK... ...MSKL-COOH ?
- ▶ Adenovirus: full length
- ▶ ????????



Mouse Immunizations

- 1996/97 (Diabor Oy, Matti Höyhtyä): 2 mg of baculoviral $\Delta N\Delta C$ -hVEGF-C-H₆ (DP-TEETIK...MSKLH₆)
- 1997/98 (Vijay Kumar/Reija Valtola): yeast $\Delta N\Delta C$ -hVEGF-C-H₆ (EA/EA/YVEF-TEETIK...MSKLH₆)
- 2003 (Haartman Institute, Tanja/Salla): yeast protein as above, same expression batch?
- 2003 (HUS, Ulf-Håkan Stenman): 2 mg of baculoviral hVEGF-C-FL-H₆ (DP-FESGLD...PQMSH₆)

Addiitonal antibodies?

- No specific antibodies against the C-terminus of VEGF-C
- Most of our polyclonal antibodies have a high background
- Immunopurification
- E.coli protein as antigen and for immunopurification?
- New E.coli proteins:
 - VEGF-C C-terminus*
 - hPodoplanin-EC-H₈*
 - hPodoplanin-EC*
 - VEGFR-1 domain 2*
 - VEGFR-2 domain 2*

Bacterial proteins




Baculovirus work

- Baculoviruses with Dual Insect/Mammalian Promoter
- Protein Production and Purification
- What sucks about the baculovirus system and insect cells in general

What sucks



- Incubators are constantly broken
- Stock virus production
- Stock virus storage (-70°C)
- No good stock virus anymore for any VEGF-C producing virus due to "suboptimal" storage
 - titre of full-length VEGF-C virus deteriorated from $0.5 \cdot 10^7$ PFU/ml to 720 PFU/ml
 - last batch of short VEGF-C yielded only 140µg from 250ml instead of expected ~1mg
 - new plaque purifications necessary if protein production has to be continued



Expression of hLYVE-1-EC-hlgGfc in insect cells (HF)

straight Western: anti-hlgG

IP: PAS (from 1 ml sup)
Western: anti-hlgG



Expression of hLYVE-1-EC-hlgGFc in mammalian cells


293T


Cos-1

baculovirus trans-
infected infected

promoter

promoter







Dual promoter lacZ

lacZ baculo- infected d 13 CAM

infection with concentrated
virus, harvest 48 h p.i.



Dual promoter lacZ




Polh promoter VEGF-C

CAM: H&E



CAM: X-Gal



Virus Purification

Classical purification by
ultracentrifugation in a gradient,
recovery of infectivity ~5-15%

Chromatography on heparin column,
recovery >50%???

Construct Testing

No possibility to test functionality of
constructs short of creating the virus

New Baculoviruses for In-vivo Infection

- 👁 pFB1-Dual-lacZ-H₆ → works
- 👁 pFB1-Dual-IgKSP-hSA-H_{2x6} → works
- 👁 pFB1-Dual-IgKSP-CAC-H₆ → no expression
- 👁 pFB1-Dual-IgKSP-ACA-H₆ → no expression
- 👁 pFB1-Dual-IgKSP-hVEGF-C-Cterminus-H₆ → no expression
- 👁 pFB1-Dual-IgKSP-hVEGF-A₁₆₅-H₆ → untested
- 👁 pFB1-Dual-IgKSP-ΔNΔC-hVEGF-C-H₆ → untested
- 👁 pFB1-Dual-IgKSP-hVEGF-C-FL-H₆ → untested
- 👁 pFB1-Dual-IgKSP-hVEGF-C-SIIS-H₆ → untested
- 👁 pFB1-Dual-IgKSP-hVEGF-C-SIIS-FLAG-H₆ → untested

From cDNA to Protein

Step	Minimum time needed
<i>Cloning of cDNA into baculovirus transfer vector</i>	5 days
<i>Transposition in E.coli to create recombinant virus</i>	4 days
<i>Transfection of insect cells with viral DNA</i>	4 days
<i>1. Amplification of virus stock</i>	4 days
<i>Testing of different clones for expression</i>	6 days
<i>2. Amplification of selected clones</i>	4 days
<i>Large scale production of virus stock</i>	4 days
<i>Infection of insect cells for production purposes</i>	3 days
<i>Dialysis of conditioned medium</i>	3 days
<i>Purification using Ni²⁺NTA chromatography</i>	1 day
<i>Dialysis, sterilization & quantitation of peak fraction</i>	3 days
<i>Total</i>	41 days

Protein Yields

<i>Protein</i>	<i>µg/ml*</i>
<i>Low-level expression: full-length VEGF-C, full-length VEGF-D</i>	0.2-1
<i>Medium-level expression: short VEGF-C-C156S, short VEGF-D, VEGF-A₁₆₅, most IgG fusions</i>	1-4
<i>High-level expression: short VEGF-C</i>	5-10
<i>Insane levels: VEGF-E</i>	>10

* µg purified & sterile protein per ml conditioned medium using approx. 500 ml conditioned medium

Small vs. large scale expression

- Protein yields do not scale
- Small scale expression is inefficient due to losses during purification, dialysis & sterilization (100 ml vs. 500 ml gives 17µg vs. 500µg hVEGF-C-FL)
- Large scale expression of hVEGF-C-FL from baculovirus not feasible (problems of air-lift fermenter: stock virus **quantity** & quality, cell viability & cell lines, monitoring, control)
- Problem of storing stockvirus (lots of -70 °C space needed)
- Stable expression for large scale expression might be easier (*Drosophila* & InsectSelect)

Drosophila Expression System (DES)

Schneider/S2 cells

Advantages over baculovirus system

- Transient or stable
- Induceable or constitutive expression
- Stable cells can be frozen
- No stockvirus needed

Disadvantages

- Expression levels approx. 1/3 of baculovirus system
- S2 cells grow terribly slow
- S2 cells are difficult to thaw
- Selection takes 3 weeks

New stable S2 cell lines

- pMT-bipSP-VEGFR-3-EC/IgGFc (T. Kärpänen)
- pMT-bipSP-hVEGF-C-FL
- pMT-bipSP-hVEGF-C-FL-H₆
- pMT-endSP-hVEGF-C-FL
- pMT-endSP-hVEGF-C-FL-H₆
- pMT-hygro-bipSP-hVEGF-C-FL
- pMT-hygro-bipSP-hVEGF-C-FL-H₆
- v1 pMT-hygro-endSP-hVEGF-C-FL-H₆
- v2 pMT-hygro-endSP-hVEGF-C-FL-H₆
- pMT-hygro-endSP-hVEGF-C-FL

InsectSelect

Similar to DES

- HighFive or Sf9/21 cells: grow faster and are easier to freeze/thaw than S2 cells
- No co-transfection with selection plasmid needed
- No good selection markers available (only zeocin & blasticidin)

Major disadvantage

- Stable HighFive or Sf9/21 cells will become sooner or later infected with baculovirus if baculovirus work is done in the same lab

New InsectSelect stable cell lines

- pIZ-melSP-hVEGF-C-FL-H₆
- pIZ-melSP-hVEGF-C-FL
- pIZ-hVEGF-C-FL-H₆
- pIZ-hVEGF-C-FL

both HighFive and Sf-9 cells
both in serum-free and 10%FCS containing media

Insect cell trouble

Common disadvantages

- 👁 All insect cells are relatively difficult to transfect (S2: Only Ca phosphate, max 10%)
- 👁 AAV for infection of insect cells and creation of stable cell lines?




Alanin scan of VEGF-C

AHYNTEILKSIDNEWRIKTCMPREVCIDVGKEFGVATNTFFKPPCVSVYRCGGCCNSEGLQCMNTSTSYLSKTLFEITVPLSQGPKPVTISFANHTSCRCMSKLD

F
G
V
FGV
T
N
T
TNTF

P
C
V
S
V
Y
SVY


T
V
P
L
S
L (deletion)
S (deletion)
LS (deletion)
Q
G
P
K
P
V
T
I



→ around 30 additional mutants due to overcycling

© Michael Jeltsch

AAV constructs of Hybrids




Antibody didn't work

psubCMV-WPRE

hVEGF-R1/IgGF_c

A_12-11_A
A_84-11_A
VEGF-A₁₆₅
empty vector
C_12-11_C
C_84-11_C



Refolding

- 32 different conditions
sparse matrix screen according to Chen & Gouaux (1997)
and all published VEGF/PDGF refolding conditons
- Buy ready if you can
- 5 different proteins
 - hVEGF-A₈₋₁₀₉ (as published)
 - hVEGF-C₁₁₂₋₂₁₆ (equivalent to hVEGF-A8-109)
 - hVEGF-C₁₀₃₋₂₁₅ (equivalent to baculovirus short VEGF-C protein)
 - hVEGFR-1 domain 2 (as published)
 - hVEGFR-2 domain 2 (equivalent to hVEGFR-1 domain 2)

Testing refolded proteins

- Stimulation of tyrosine phosphorylation (PAE-VEGFR-3 cells) with dialyzed refolded protein
- all cells died probably to wrong concentration of puromycin stock solution

Proposed VEGF-C naming

- VEGF-C₁₀₃₋₂₂₇ TEETIK... ..SIIRR
native short VEGF-C (PC3 cells)
- VEGF-C₁₁₂₋₂₂₇ AHYNT... ..SIIRR
native short VEGF-C (293 cells)
- VEGF-C₁₀₃₋₂₁₅ TEETIK... ..MSKL
short baculovirus protein, crystallization
- VEGF-C₁₁₂₋₂₁₆ AHYNT... ..MSKLD
crystallization

Molecular/Cancer Biology Research Program

University of Helsinki

Finland



Kari Alitalo

Katja Kerkelä

Terhi Kärpänen

Tanja Pyy